Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver.
Firas BaidounZahi MerjanehRama NanahAnas M SaadOmar Abdel-RahmanPublished in: Journal of comparative effectiveness research (2022)
Aim: Compare overall survival (OS) between adjuvant and neoadjuvant chemotherapy and analyze the effect of chemotherapy on OS. Materials & methods: National Cancer Database was queried for patients diagnosed with metastatic colorectal adenocarcinoma with isolated liver metastases between 2004 and 2016. We evaluated the OS and chemotherapy effect using Kaplan-Meier estimates and multivariable cox regression analyses. Results: Total 6883 patients with metastatic colorectal cancer and liver metastases were included, of which 6042 patients were treated with surgery and chemotherapy and 841 patients were treated with surgery only. Patients who received neoadjuvant chemotherapy had better OS compared with patients who received adjuvant chemotherapy. Conclusion: Patients with colorectal cancer with isolated liver metastases who were treated with neoadjuvant chemotherapy had better OS compared with adjuvant chemotherapy.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- liver metastases
- newly diagnosed
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- lymph node
- metastatic colorectal cancer
- rectal cancer
- chronic kidney disease
- sentinel lymph node
- minimally invasive
- emergency department
- small cell lung cancer
- early stage
- radiation therapy
- patient reported outcomes